Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents

Annals of Oncology

Volumn 12, Issue 11, 2001, Pages 1515-1525

  Sekine, I ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Anticancer agents; Polymorphism; Transporter protein

Indexed keywords

ACYLTRANSFERASE; ANION; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CATION; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; ETOPOSIDE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SORIVUDINE; TEGAFUR; TENIPOSIDE; THIOPURINE METHYLTRANSFERASE; UFT; URACIL; VINBLASTINE; VINCRISTINE; VINDESINE;

ANIMAL CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INHERITANCE; LIVER DYSFUNCTION; MEMBRANE TRANSPORT; METABOLIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; TREATMENT FAILURE;

EID: 0035692767     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013164013375     Document Type: Review

References (110)

1. Pharmacogenetics in biological perspective
2. 5-fluoropyrimidines
3. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
4. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
5. The oral fluoropyrimidines in cancer chemotherapy
6. Uracil-tegafur in gastric carcinoma: A comprehensive review
7. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism
8. Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency
9. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer
10. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
11. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
12. Population study of dihydropyrimidine dehydrogenase in cancer patients
13. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients
14. Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil
15. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
16. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
17. Pharmacogenetics
18. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer
19. Individualization of cancer therapy based on cytochrome P450 polymorphism: A pharmacogenetic approach
20. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
21. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide
22. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes
23. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
24. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation
25. Metabolic activation of dacarbazine by human cytochromes P450: The role of CYP1A1, CYP1A2, and CYP2E1
26. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism
27. N,N′-N″-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents
28. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence-dependency in high-dose chemotherapy regimens
29. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate
30. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro
31. Human cytochrome P450 metabolism of teniposide and etoposide
32. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
33. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes
34. Topoisomerase II inhibitors: The epipodophyllotoxins, m-AMSA, and the ellipticine derivatives
35. Pharmacokinetics of anticancer agents in patients with impaired liver function
36. Antimicrotubule agents
37. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity
38. Molecular genetics of the human cytochrome P450 monooxygenase superfamily
39. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance
40. More about: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
41. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
42. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
43. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis
44. NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues
45. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms
46. Human FAD-dependent NAD(P)H diaphorase
47. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy
48. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone
49. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:Quinone oxidoreductase polymorphism
50. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
51. Chapter 20. Polymorphic NATs and cancer predisposition
52. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study
53. Phase I study of amonafide dosing based on acetylator phenotype
54. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
55. Pharmacogenetics of cancer therapy: Getting personal
56. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism
57. Glutathione S-transferases: Biomedical applications
58. Haracterization and chromosome location of the gene GSTZ1 encoding the human Zeta class glutathione transferase and maleylacetoacetate isomerase
59. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
60. Glutathione-related mechanisms in cellular resistance to anticancer drugs
61. Glutathione-associated enzymes in anticancer drug resistance
62. Upregulation of glutathione S-transferase activity in enterocytes of young children
63. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro
64. Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis
65. The glutathione S-transferases: Influence of polymorphism on cancer susceptibility
66. The human glutathione S-transferases: Studies on the tissue distribution and genetic variation of the GST1, GST2 and GST3 isozymes
67. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
68. Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia
69. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
70. The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients
71. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease
72. Glucuronidation in humans. Pharmacogenetic and developmental aspects
73. Hereditary jaundice and disorders of bilirubin metabolism
74. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
75. Metabolism of epirubicin to glucuronides: Relationship to the pharmacodynamics of the drug
76. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan
77. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
78. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
79. Epirubicin in a breast cancer patient with Gilbert's syndrome: Apparent lack of major pharmacokinetic alterations
80. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
81. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
82. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
83. Hepatobiliary transport
84. Cellular and molecular aspects of drug transport in the kidney
85. An inventory of the human ABC proteins
86. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs
87. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
88. P-glycoprotein and pharmacokinetics
89. A family of drug transporters: The multidrug resistance-associated proteins
90. Structural, mechanistic and clinical aspects of MRP1
91. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome
92. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome
93. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome
94. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
95. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (MRP3)
96. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
97. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
98. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone and topotecan-resistant cell lines
99. Expression of multidrug resistance-related transporters in human breast carcinoma
100. The multispecific organic anion transporter (OAT) family
101. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta
102. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter
103. Interaction between nonsteroidal anti-inflammatory drugs and high-dose methotrexate: A literature review
104. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide
105. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
106. Functional analysis of rat renal organic anion transporter OAT-K1: Bidirectional methotrexate transport in apical membrane
107. Nucleoside and nucleobase transport systems of mammalian cells
108. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters
109. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models
110. What have we learnt thus far from mice with disrupted P-glycoprotein genes?